[1] Bergeron RJ, et al. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem. 2012 Aug 23;55(16):7090-103. DOI:
10.1021/jm300509y[2] Basu S, et al. Understanding the intricacies of iron overload associated with β-thalassemia: a comprehensive review[J]. Thalassemia Reports, 2023, 13(3): 179-194.
[3] Taher A T, et al. Safety and pharmacokinetics of the oral iron chelator SP‐420 in β‐thalassemia[J]. American Journal of Hematology, 2017, 92(12): 1356-1361. DOI:
10.1002/ajh.24914